1997
DOI: 10.1038/sj.leu.2400870
|View full text |Cite
|
Sign up to set email alerts
|

Proliferative effects of several hematopoietic growth factors on acute myelogenous leukemia cells and correlation with treatment outcome

Abstract: The response of human acute myelogenous leukemia (AML) cells to four different hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 ␤ (IL-1␤), interleukin-3 (IL-3), and stem cell factor (SCF)) and the relationship of the proliferative response of the AML cells to treatment outcome were studied. Proliferative responses were analyzed in 79 patients with de novo AML and 19 patients with AML arising from myelodysplastic syndrome (MDS). In de novo AML, a positive pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
13
0

Year Published

2000
2000
2009
2009

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(14 citation statements)
references
References 21 publications
1
13
0
Order By: Relevance
“…43 Sensitivity of blast cells to GM-CSF in vitro appeared to be inversely related with early treatment response which may be explained by the autocrine production of hematopoietic growth factors in AML blasts. [44][45][46][47] These results were confirmed by Tsuzuki and coworkers, 48 showing that patients whose leukemic cells had a positive proliferative response to growth factors had a poorer outcome.…”
Section: Introductionsupporting
confidence: 77%
“…43 Sensitivity of blast cells to GM-CSF in vitro appeared to be inversely related with early treatment response which may be explained by the autocrine production of hematopoietic growth factors in AML blasts. [44][45][46][47] These results were confirmed by Tsuzuki and coworkers, 48 showing that patients whose leukemic cells had a positive proliferative response to growth factors had a poorer outcome.…”
Section: Introductionsupporting
confidence: 77%
“…A similar, though less significant, correlation was also observed in cytokine-stimulated cultures. 44 It therefore seems opportune to re-evaluate a large group of AML samples, that exclude patients carrying a Flt3/ITD mutation, with respect to growth factor response and patient prognosis.…”
Section: Discussionmentioning
confidence: 99%
“…26,27 Correlations between the in vitro cytokine responsiveness and patient prognosis have been previously been reported. [28][29][30] Our observation that patients with a Flt3/ITD comprise a 'low' cytokine responder population coupled to a poor prognosis, combined with the poor prognosis of patients with an age over 60 years, led us to define our intermediate risk population as that population of primary AML patients with an age below 60 years not having a tandem duplication in the Flt3 gene and with intermediate risk cytogenetics. Here, we show that among this intermediate risk population, poor and good risk patient prognosis can be further stratified based on the short-term (7-day) in vitro response to either G-CSF or IL-1␣.…”
Section: Discussionmentioning
confidence: 99%